CNS Pharmaceuticals Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Rami Levin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	1.5yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 15

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals press release (NASDAQ:CNSP): Q2 Net Loss of $3.6M As of June 30, 2022, the company had cash of approximately $9M and working capital of approximately $10.5M. The company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into 2023.

Analysis Article • Dec 04

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO

Rami Levin (57 yo)

less than a year

Tenure

Mr. Rami Levin, M.B.A. Director of CNS Pharmaceuticals, Inc. from December 2025 and serves as its President & CEO since January 01, 2026. Mr. Levin served as President at Saniona AB (publ) since January 7,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Downs	Senior Vice President of Finance	less than a year	US$594.00k	0.00021% $ 15.9
Rami Levin	President	less than a year	no data	no data
Steve O'Loughlin	Chief Financial Officer	less than a year	no data	no data
Eric Faulkner	Chief Technology Officer	less than a year	no data	no data
Dylan Wenke	Chief Business Officer	less than a year	no data	no data
E. Kelley	Chief Medical Officer	less than a year	no data	no data

0.3yrs

Average Tenure

53yo

Average Age

Experienced Management: CNSP's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Rami Levin	President	less than a year	no data	no data
Faith Charles	Independent Chairman of Board	3.6yrs	US$81.50k	0.49% $ 36.7k
Roger Stupp	Scientific Advisory Panel	less than a year	no data	no data
Jeffry Keyes	Independent Director	8.1yrs	US$61.00k	0% $ 0
Bettina Cockroft	Independent Director	3.2yrs	US$54.00k	0% $ 0
Amy Mahery	Independent Director	2.4yrs	US$59.28k	0% $ 0
Timothy Cloughesy	Scientific Advisory Panel	1.5yrs	no data	no data
Mark Gilbert	Scientific Advisory Panel	1.5yrs	no data	no data
Michal Fisher	Independent Director	less than a year	no data	no data

1.5yrs

Average Tenure

55yo

Average Age

Experienced Board: CNSP's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/12 04:49
End of Day Share Price	2026/07/10 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CNS Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bruce Jackson	Benchmark Company
Robert LeBoyer	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

CNS Pharmaceuticals Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

Recent updates

CNS Pharmaceuticals, Inc. announced that it expects to receive $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners

New major risk - Share price stability

New minor risk - Share price stability

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

New major risk - Financial position

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.996373 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14 million.

New major risk - Financial position

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Revenue and earnings growth

New major risk - Share price stability

Forecast to breakeven in 2027

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources